Fidelity International’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$122M Buy
875,527
+209,835
+32% +$29.4M 0.09% 214
2025
Q4
$81.7M Sell
665,692
-49,574
-7% -$6.02M 0.06% 261
2025
Q3
$79.4M Buy
715,266
+199,668
+39% +$22.7M 0.06% 263
2025
Q2
$57.2M Buy
515,598
+151,030
+41% +$16.1M 0.05% 318
2025
Q1
$40.8M Buy
364,568
+352,101
+2,824% +$36.3M 0.04% 342
2024
Q4
$1.15M Sell
12,467
-28,386
-69% -$2.56M ﹤0.01% 716
2024
Q3
$3.43M Buy
40,853
+1,821
+5% +$139K ﹤0.01% 659
2024
Q2
$2.68M Buy
39,032
+34,814
+825% +$2.32M ﹤0.01% 668
2024
Q1
$309K Buy
+4,218
New +$324K ﹤0.01% 783
2023
Q3
Sell
-86,676
Closed -$6.68M 812
2023
Q2
$6.68M Sell
86,676
-46,735
-35% -$3.73M 0.01% 534
2023
Q1
$11.1M Sell
133,411
-41,340
-24% -$3.42M 0.01% 475
2022
Q4
$15M Buy
174,751
+18,185
+12% +$1.44M 0.02% 435
2022
Q3
$9.66M Buy
156,566
+66,224
+73% +$4.18M 0.01% 497
2022
Q2
$5.58M Buy
90,342
+19,120
+27% +$1.18M 0.01% 577
2022
Q1
$4.23M Sell
71,222
-309,734
-81% -$19.8M ﹤0.01% 620
2021
Q4
$27.7M Sell
380,956
-137,158
-26% -$9.45M 0.03% 399
2021
Q3
$36.2M Sell
518,114
-42,533
-8% -$2.99M 0.04% 350
2021
Q2
$38.6M Buy
560,647
+15,837
+3% +$1.06M 0.04% 350
2021
Q1
$35.2M Buy
544,810
+544,522
+189,070% +$35.1M 0.04% 340
2020
Q4
$17K Sell
288
-387
-57% -$23.4K ﹤0.01% 796
2020
Q3
$43K Sell
675
-394,661
-100% -$27.4M ﹤0.01% 700
2020
Q2
$30.4M Buy
395,336
+394,575
+51,850% +$30.2M 0.04% 332
2020
Q1
$57K Sell
761
-249,621
-100% -$17.2M ﹤0.01% 662
2019
Q4
$16.3M Sell
250,382
-119,999
-32% -$7.81M 0.02% 433
2019
Q3
$23.5M Sell
370,381
-1,736,191
-82% -$113M 0.04% 352
2019
Q2
$142M Buy
2,106,572
+259,465
+14% +$17.1M 0.21% 124
2019
Q1
$120M Sell
1,847,107
-1,156,062
-38% -$76.8M 0.19% 141
2018
Q4
$188M Sell
3,003,169
-164,356
-5% -$11.5M 0.33% 81
2018
Q3
$245M Buy
3,167,525
+331,219
+12% +$25M 0.36% 69
2018
Q2
$201M Buy
2,836,306
+659,695
+30% +$46.6M 0.3% 90
2018
Q1
$164M Buy
2,176,611
+84,170
+4% +$6.69M 0.45% 59
2017
Q4
$150M Buy
2,092,441
+40,924
+2% +$3.11M 0.42% 67
2017
Q3
$166M Buy
2,051,517
+577,397
+39% +$44.2M 0.48% 55
2017
Q2
$104M Buy
1,474,120
+1,980
+0.1% +$132K 0.3% 96
2017
Q1
$100M Buy
1,472,140
+86,900
+6% +$6.11M 0.28% 96
2016
Q4
$99.2M Buy
+1,385,240
New +$103M 0.29% 94
2016
Q3
Sell
-276,000
Closed -$23M 527
2016
Q2
$23M Sell
276,000
-46,229
-14% -$4.1M 0.07% 224
2016
Q1
$29.6M Sell
322,229
-70,829
-18% -$6.39M 0.09% 202
2015
Q4
$39.8M Sell
393,058
-37,427
-9% -$3.89M 0.12% 179
2015
Q3
$42.3M Sell
430,485
-660,578
-61% -$73.4M 0.15% 159
2015
Q2
$128M Sell
1,091,063
-393,462
-27% -$43M 0.41% 71
2015
Q1
$146M Sell
1,484,525
-1,386,342
-48% -$141M 0.47% 65
2014
Q4
$271M Buy
2,870,867
+409,472
+17% +$42.3M 0.93% 23
2014
Q3
$262M Sell
2,461,395
-1,374,775
-36% -$135M 1% 21
2014
Q2
$318M Sell
3,836,170
-829,756
-18% -$64.6M 1.19% 17
2014
Q1
$331M Buy
4,665,926
+1,716,320
+58% +$135M 1.2% 13
2013
Q4
$222M Sell
2,949,606
-25,349
-0.9% -$1.77M 0.89% 21
2013
Q3
$187M Sell
2,974,955
-68,151
-2% -$4.07M 0.89% 23
2013
Q2
$156M Buy
+3,043,106
New +$159M 0.88% 22

Other funds holding GILD

Fidelity International's GILD Position: Q1 2026 in Review

Fidelity International increased its Gilead Sciences (GILD) stake by 32% in Q1 2026, buying an estimated $29.4M and bringing the position to 875,527 shares worth $122M. The position accounts for 0.09% of the portfolio, ranked #214.

Fidelity International first reported a position in GILD in Q2 2013 and has held it in 49 quarters since. The position peaked at $331M in Q1 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Fidelity International held 875,527 shares of Gilead Sciences worth $122M as of Q1 2026.
  • Fidelity International bought 209,835 Gilead Sciences shares in Q1 2026, an estimated $29.4M.
  • Gilead Sciences made up 0.09% of Fidelity International's portfolio in Q1 2026, its #214 holding.
  • Fidelity International first reported a position in Gilead Sciences in Q2 2013 and has held it in 49 quarters since.
  • Fidelity International's Gilead Sciences position peaked at $331M in Q1 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.